Imunon to issue 0.15-for-1 stock dividend, pay 21 Aug 2025

Rhea-AI Filing Summary

Imunon, Inc. filed a Form 8-K on 28 Jul 2025 reporting that its Board of Directors has approved a 15% stock dividend, equal to 0.15 additional shares for every outstanding share and each common-stock equivalent with dividend rights. The Board set 7 Aug 2025 as the record date and 21 Aug 2025 as the payment date. Exhibit 99.1 contains the related press release; no other material events, financial results, or transactions were disclosed. The information in the exhibit is furnished, not filed, under the Exchange Act.

Positive

• 15% stock dividend grants shareholders additional shares at no cost, scheduled for 21 Aug 2025.

Negative

• Total shares outstanding will rise by 15%, requiring recalculation of EPS and other per-share metrics.

Insights

Corporate Actions Analyst

TL;DR: 15% stock dividend declared; neutral value impact but raises share count and liquidity.

The 8-K solely announces a 0.15-for-1 stock dividend. While shareholders receive more shares, the economic value of the company is unchanged; the action merely redistributes equity, increasing the number of shares outstanding by 15%. This will require restatement of per-share metrics after 21 Aug 2025. No cash impact or new capital is raised, so balance-sheet leverage and cash runway remain intact. Because no operational updates accompanied the announcement, the event is corporate-action driven and carries limited fundamental significance for valuation.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

When is Imunon (IMNN) paying the 15% stock dividend?

The dividend will be payable on 21 Aug 2025 to shareholders of record as of 7 Aug 2025.

What is the size of Imunon’s announced stock dividend?

The Board approved a 15% stock dividend, or 0.15 additional shares for each existing share.

Does the stock dividend change Imunon’s cash position?

No. A stock dividend issues shares instead of cash, so no funds leave the company.

Will Imunon restate per-share metrics after the dividend?

Yes. EPS and similar metrics must be adjusted for the 15% higher share count once the dividend is effective.

Where can investors find more details about the announcement?

Additional information is in Exhibit 99.1, the press release dated 28 Jul 2025, attached to the Form 8-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 07/28/2025 - 08:10 AM Learn about SEC filing dates

false 0000749647 0000749647 2025-07-28 2025-07-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2025

Imunon, Inc.

(Exact name of registrant as specified in its Charter)

Delaware		001-15911		52-1256615
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ		08648-2311
(Address of principal executive offices)		(Zip Code)

(609) 896-9100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		IMNN		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On July 28, 2025, Imunon, Inc. (the “Company”), issued a press release announcing that the Company’s Board of Directors approved a 15% stock dividend, 0.15 shares of common stock (the “Stock Dividend”) per share of the Company’s issued and outstanding shares of common stock, par value $0.01 per share (the “Common Stock”), and per each common stock equivalent with dividend rights.

The Board of Directors has fixed August 7, 2025 as the record date (the “Record Date”) for the Stock Dividend, and the Stock Dividend will be payable on August 21, 2025 to stockholders of record as of the Record Date.

The information contained in Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated July 28, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMUNON INC.
Dated: July 28, 2025	By:	/s/ Susan Eylward
		Susan Eylward
		General Counsel and Corporate Secretary